4
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T37235 |
(±)16(17)-EpDPA
(±)16,17-EpDPE,(±)16,17 EDP,(±)16,17-epoxy Docosapentaenoic Acid,(±)16,17-epoxy DPA,(±)16(17)-EpDPA |
Others | Others |
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahex... | |||
T35497 |
(±)7(8)-EpDPA
|
Others | Others |
Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA is an epoxide derivative of DHA that is generated by the action of cytochrome P450 epoxygenases. It is naturally occurring in plasma and brain and spinal cord tissues and is increased following dietary supplementation with ω-3 fatty acids. (±)7(8)-EpDPA and other epoxy metabolites of DHA modulate receptor and channel activities to evoke diverse effects, such as promoting ... | |||
T37238 |
(±)19(20)-EpDPA
|
Others | Others |
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators. Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EpETrE which are prime candidates for the actual active mediator. However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic... | |||
T36218 |
19R(20S)-EpDPA
|
Others | Others |
19R(20S)-EpDPA is an oxylipin and a metabolite of docosahexaenoic acid .1,2It is formed from DHA by various cytochrome P450 (CYP) isoforms in a stereoselective manner.219R(20S)-EpDPA (30 nM) prevents calcium-induced increases in the spontaneous beating of isolated neonatal rat cardiomyocytes (NRCMs).3 1.Cinelli, M.A., Yang, J., Scharmen, A., et al.Enzymatic synthesis and chemical inversion provide both enantiomers of bioactive epoxydocosapentaenoic acidsJ. Lipid Res.59(11)2237-2252(2018) 2.Lucas... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-00423 |
FGFR2 Protein, Human, Recombinant (alpha IIIb, hFc)
BFR-1,KGFR,TK25,JWS,ECT1,K-SAM,FGFR2 α(IIIb),CD332,fibroblas... |
Human | HEK293 Cells |
FGFR2 Protein, Human, Recombinant (alpha IIIb, hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 66.3 kDa and the accession number is P21802-17. | |||
TMPY-02555 |
VSTM1 Protein, Human, Recombinant (His)
SIRL-1,UNQ3033,MGC119161,V-set and transmembrane do... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... | |||
TMPY-02563 |
VSTM1 Protein, Human, Recombinant (hFc)
VSTM1,V-set and transmembrane domain containing 1,SIRL1,UNQ3... |
Human | HEK293 Cells |
V-set and transmembrane domain containing 1 (VSTM1) is a protein containing the V-set domains. V-set domains are immunoglobulin-like domains resembling the antibody variable region. V-set domains are found in many kinds of protein families, including immunoglobulin light and heavy chains, several T-cells such as CD2, CD4, CD80, and CD86, myelin membrane adhesion molecules, junction adhesion molecules (JAM), tyrosine-protein kinase receptors, and the programmed cell death protein1. VSTM1 Protein,... |